Volume 24, Number 10—October 2018
Research
Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
Table 3
Characteristic |
No. patients |
FEDO, median (SD) |
p value† |
---|---|---|---|
Demographic and socioeconomic | |||
Site type | |||
Urban county | 248 | 92.8 (13.3) | 0.51 |
Rural county | 26 | 94.2 (15.4) | |
Age, y, correlation coefficient | 272 | −0.03 | 0.63 |
Months on treatment, correlation coefficient | 272 | −0.14 | 0.02 |
Education | |||
<Primary school | 26 | 88.4 (13.7) | 0.17 |
High school | 105 | 93.0 (14.5) | |
Some college or technical school | 67 | 93.9 (13.2) | |
>Bachelor’s degree | 71 | 94.2 (11.9) | |
Sex | |||
M | 167 | 92.8 (12.7) | 0.70 |
F | 105 | 93.4 (14.8) | |
Race or ethnicity | |||
Asian | 154 | 95.0 (10.8) | <0.001 |
Caucasian or white | 19 | 95.6 (15.4) | |
Hispanic or Latino | 82 | 86.8 (16.3) | |
Other‡ | 17 | 87.0 (11.4) | |
Country of birth | |||
United States | 47 | 90.3 (17.2) | <0.001 |
Mexico | 44 | 84.7 (16.0) | |
Other§ | 181 | 94.5 (10.7) | |
Annual household income, $ (USD) | |||
<10,000 | 110 | 92.7 (13.6) | 0.04 |
10,000–30,000 | 74 | 90.8 (14.8) | |
30,000–50,000 | 26 | 92.0 (10.4) | |
>50,000 | 39 | 96.3 (9.8) | |
Insured at baseline | |||
Yes | 229 | 93.4 (13.6) | 0.28 |
No | 42 | 89.9 (13.4) | |
Owned cell phone at baseline | |||
Yes | 247 | 93.0 (12.9) | 0.49 |
No | 26 | 93.1 (18.3) | |
Owned smartphone at baseline | |||
Yes | 196 | 92.8 (13.2) | 0.84 |
No |
76 |
93.6 (14.5) |
|
Tuberculosis risk factors | |||
Ever smoked cigarettes | |||
Yes | 116 | 92.3 (12.3) | 0.26 |
No | 157 | 93.6 (14.4) | |
Marijuana use in previous 6 mo | |||
Yes | 18 | 88.1 (19.3) | 0.01 |
No |
252 |
93.2 (13.0) |
|
Tuberculosis and treatment perceptions | |||
Did you share your VDOT experience with family members? | |||
Yes | 156 | 92.9 (14.1) | 0.80 |
No | 58 | 93.1 (13.0) | |
Did you share your VDOT experience with friends, neighbors, classmates, or coworkers? | |||
Yes | 73 | 93.4 (13.7) | 0.48 |
No | 141 | 92.7 (13.9) | |
Were you concerned someone would see you using the VDOT cell phone? | |||
Yes | 73 | 93.3 (14.9) | 0.89 |
No | 141 | 92.6 (13.2) | |
Did you ever fail to record a video because you were worried someone was watching you? | |||
Yes | 18 | 89.2 (10.3) | 0.28 |
No | 196 | 93.1 (14.1) | |
Confidentiality of VDOT vs. DOT? | |||
More | 146 | 92.9 (14.4) | 0.92 |
Less | 5 | 92.7 (12.5) | |
Same | 59 | 93.0 (12.7) | |
VDOT experience | |||
Overall, how easy/difficult did you find the VDOT process? | |||
Very easy | 174 | 93.6 (12.4) | 0.001 |
Somewhat easy | 32 | 91.7 (14.6) | |
Somewhat or very difficult | 9 | 66.9 (19.8) | |
If you had to redo tuberculosis treatment, would you choose VDOT or in-person DOT? | |||
VDOT | 192 | 93.2 (13.9) | |
In-person DOT | 6 | 91.3 (13.3) | 0.55 |
No preference | 16 | 92.1 (12.9) | |
Would you recommend VDOT to other tuberculosis patients? | |||
Yes | 202 | 92.7 (13.9) | 0.42 |
No | 8 | 94.8 (9.8) | |
How often did you take tuberculosis while medication away from home? | |||
Never or rarely | 120 | 94.2 (12.3) | 0.04 |
Less than half or half the time | 48 | 93.4 (13.8) | |
Most of the time or every time | 46 | 88.9 (16.4) | |
How often did you have problems using the VDOT application? | |||
Never | 82 | 95.1 (13.7) | 0.001 |
Rarely | 99 | 92.8 (10.3) | |
Less than half the time | 23 | 88.2 (12.3) | |
Half the time or more | 10 | 74.3 (25.7) | |
How often did poor reception cause you problems uploading videos? | |||
Never | 65 | 95.8 (15.6) | 0.01 |
Rarely | 103 | 92.4 (11.5) | |
Less than half the time | 24 | 89.6 (8.7) | |
Half the time or more | 20 | 84.9 (19.3) |
*DOT, directly observed therapy; FEDO, fraction of expected doses observed = number of complete doses observed through VDOT divided by the number of doses expected; VDOT, video directly observed therapy.
†p values based on Wilcoxon rank sum test, Kruskal-Wallis test, or Spearmen correlation coefficient.
‡Other race groups were African American (n = 3), American Indian (n = 2), Pacific Islander (n = 1), and mixed and other races (n = 11).
§Other countries were predominately in Asia.
Page created: September 16, 2018
Page updated: September 16, 2018
Page reviewed: September 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.